Market Place
Sourcing Support
X4 Pharma Reports Positive Phase 2 Results in Chronic Neutropenia
13 Nov 2024 //
GLOBENEWSWIRE
X4 Pharma Reports Q3 2024 Financial Results & Corporate Update
13 Nov 2024 //
GLOBENEWSWIRE
X4 Pharmaceuticals Reports Q2 2024 Results And Corporate Updates
08 Aug 2024 //
GLOBENEWSWIRE
X4 Pharma Announces +ve Data from Ongoing Six-Month Ph2 Trial of Mavorixafor
27 Jun 2024 //
GLOBENEWSWIRE
X4 Pharma Investor Event On New Mavorixafor Chronic Neutropenia Data
29 May 2024 //
GLOBENEWSWIRE
X4 Pharma $125M From Voucher Sale, Loan Drawdown
09 May 2024 //
GLOBENEWSWIRE
X4 enters commercial fold with FDA approval of rare disease drug Xolremdi
30 Apr 2024 //
FIERCE PHARMA
PANTHERx® Rare Partnering with X4 for XOLREMDI™ Distribution
29 Apr 2024 //
PR NEWSWIRE
X4 Pharma`s XOLREMDI™ Approved by FDA for WHIM Syndrome
29 Apr 2024 //
GLOBENEWSWIRE
X4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2023 Financial Results
21 Mar 2024 //
GLOBENEWSWIRE
X4 Pharma Announces Presentation of Data from Mavorixafor Phase 2 Trial
09 Dec 2023 //
GLOBENEWSWIRE
X4 Pharmaceuticals Announces FDA Acceptance with Priority Review for Mavorixafor
31 Oct 2023 //
GLOBENEWSWIRE
X4 Pharmaceuticals’ Presentations at ASH 2022 Further Highlight for Mavorixafor
12 Dec 2022 //
GLOBENEWSWIRE
X4 scores a phase 3 win for immune deficiency disorder drug
30 Nov 2022 //
FIERCEBIOTECH
X4 Pharmaceuticals Announces Positive Top-Line Results from 4WHIM Global
29 Nov 2022 //
GLOBENEWSWIRE
X4 Pharmaceuticals Host Investor Webinar Highlighting New Mavorixafor Phase 1b
31 Aug 2022 //
GLOBENEWSWIRE
X4 Receives Rare Pediatric Disease Designation from FDA for Mavorixafor
10 Dec 2020 //
GLOBENEWSWIRE
X4 Pharma Presents Positive Clinical Data from Ph2 Study of Mavorixafor
11 Jun 2020 //
GLOBENEWSWIRE
X4 Pharma Announces Data from Phase 2 Open-Label Extension Trial of Mavorixafor
14 May 2020 //
BUSINESSWIRE
X4 Pharma Heads to NASDAQ Via Reverse Merger with Arsanis
28 Nov 2018 //
XCONOMY
X4 Pharmaceuticals Secures $27 Million in Series B Financing
16 Nov 2017 //
PRESS RELEASE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.